Joint Pain Injections Market Size, Share & Industry Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

The global joint pain injections market size was valued at USD 5.25 billion in 2023, and is projected to grow from USD 5.77 billion in 2024 to USD 12.71 billion by 2032, exhibiting a CAGR of 10.4% during the forecast period. North America dominated the joint pain injections market with a market share of 45.14% in 2023. Moreover, the U.S. joint pain injection market is projected to grow significantly, reaching an estimated value of USD 5.49 billion by 2032, driven by the rising incidence of sports injuries and awareness regarding joint disorders.

Joint pain injections are an effective method for reducing inflammation and managing pain among patients who have various musculoskeletal disorders, including rheumatoid arthritis, psoriatic arthritis, and others. The corticosteroid injections are usually the first line of pain management. They are delivered directly to the painful area in the patients. The growing prevalence of several musculoskeletal disorders, such as osteoarthritis and rheumatoid arthritis, among others in the general population, is leading to a large patient pool requiring treatment. The increasing focus of the players operating in the market on developing and introducing novel therapies and products to cater to the rising demand is expected to augment market growth.

Moreover, the growing number of treatments is attributed to the favorable reimbursement policies in developed countries. In addition, the increasing awareness of the benefits of intra-articular injections in treating joint pain is responsible for the rising demand for joint pain injections.

• According to a 2021 report published by Versus Arthritis, approximately 20 million people in the U.K. suffer from a musculoskeletal condition (MSK) such as arthritis and others.

The market witnessed a decline during the COVID-19 pandemic due to reduced patient visits for treatment, thereby decreasing the overall demand for joint pain injections. However, the rising prevalence of musculoskeletal conditions among the general population and the robust focus of the key market players on developing and introducing novel products are anticipated to fuel the market growth during the forecast period.

Joint Pain Injections Market Trends

Growing Preference for Minimally Invasive Procedures Among the Patient Population Globally

The recent advancements in the pharmaceutical industry are leading to the development of novel therapies and treatment options for the management of various musculoskeletal conditions, including osteoarthritis, among others.

The increasing awareness about minimally invasive procedures for the treatment and management of these conditions and rising benefits of the procedures, such as rapid adsorption of the drug, more extended relief period for patients, less pain, and others, are resulting in a rising preference for such procedures among the patient population.

• For instance, in August 2021, Bioventus completed its investment in Trice Medical, Inc., one of the leading companies focused on developing and commercializing minimally invasive technologies for sports medicines and orthopedic surgical procedures.

Furthermore, the rising focus of the key players operating in the market on increasing their R&D activities to develop and introduce minimally invasive treatment options is a significant trend involved in the development of innovative treatment solutions such as platelet-rich plasma injections and plasma matrix therapy. In addition, ongoing research activities highlight benefits associated with novel treatments, which support the adoption of innovative products.

• According to an article published by the U.S. National Library of Medicine in July 2022, phase 3 clinical trials are carried out by Emory University on the effectiveness of injection with the composition constituting Mesenchymal Stem Cell (MSC) preparations from autologous Bone Marrow Concentrate (BMAC) and human mesenchymal stem cells manufactured from Umbilical Cord Tissue (UCT) for the treatment of knee osteoarthritis.

Therefore, the introduction of innovative products in the market is responsible for increasing the shift of preference toward joint pain injections.

Joint Pain Injections Market Growth Factors

Rising Number of Sports Injuries and Growing Awareness of Musculoskeletal Disorders to Boost Market Growth 

The increasing cases of sports injuries, such as ligament and muscle injuries globally, are resulting in a rising patient population suffering from chronic pain and other bone disorders. The increasing patient population is leading to a growing demand for pain management therapies such as joint pain injections, among others.

• According to 2022 data published by the National Safety Council (NSC), there were more than 445,000 injuries related to exercise equipment in the U.S.

The rising number of injuries, increasing initiatives by the government and other national organizations to increase awareness regarding musculoskeletal conditions, and the availability of various treatment options are expected to boost the demand for these products.

In addition, increasing per capita expenditure on healthcare in developed countries and new product launches by market players bolster the demand for intra-articular injections in the global market.

RESTRAINING FACTORS

High Cost Associated with the Products May Hamper their Adoption in Emerging Countries

The benefits of joint pain injections, including HA injections and PRP injections, among others, are a significant factor contributing to the rising penetration of these devices among the general population in the U.S., Germany, France, and others. However, the relatively high cost of these products as compared to other forms of medications is one of the major factors expected to limit the adoption of the devices.

• For instance, according to a 2021 article published by the Arizona Pain and Spine Institute, PRP injections cost around USD 500 – USD 2,000 per injection in the U.S. The patients are usually required to take two to three doses of the injections for better results.

Along with this, the availability of alternative treatment options for pain management, including oral drugs and sprays, among others, is expected to hinder the adoption of joint pain injections in emerging countries.

• According to a 2022 article published by the National Center of Biotechnology Information (NCBI), a course of physical therapy was more cost-effective than a course of glucocorticoid injections for patients with knee osteoarthritis.

Limited reimbursement policies for these products in developing countries are further anticipated to limit the adoption of these injections among the patient population, discouraging the joint pain injections market growth. Moreover, the lack of awareness about these products in developing countries is accountable for the lower adoption of intra-articular injections in the treatment of joint pain.

Joint Pain Injections Market Segmentation Analysis

By Product Analysis

Growing Patient Pool Suffering from Osteoarthritis to Propel the Hyaluronic Acid Injections Segment Expansion

Based on product, the market is segmented into corticosteroid injections, hyaluronic acid injections, platelet rich plasma injections, and others.

The hyaluronic acid injections segment dominated the market in 2023. The dominance was due to the rising patient pool suffering from osteoarthritis and increasing awareness regarding the clinical efficiency of HA injections.

The rising support of government authorities to promote treatment options among patients in several countries is another major factor contributing to the growth of the segment. Along with this, the increasing regulatory and ethical approvals by the regulatory bodies to continue the clinical trials is another significant factor contributing to the growth of the segment.

• For instance, in April 2023, Synartro AB received the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start phase 1/2a, the first-in-human clinical study of the investigational drug candidate SYN321 for the treatment of knee osteoarthritis.

The corticosteroid injections segment is expected to grow at a considerable CAGR during the forecast period. The growth of the segment is attributed to the rising use of these injections as the first line of treatment for osteoarthritis, among other joint pain disorders. The growing patient pool undergoing diagnosis and treatment is a significant factor supporting the segmental growth in the market.

The platelet rich plasma injections segment is anticipated to grow at the highest CAGR during the forecast period, owing to the rising clinical studies demonstrating positive and efficient results of these injections in pain management in patients with osteoarthritis.

• According to a 2021 article published by Baylor College of Medicine, a single PRP injection in patients with knee osteoarthritis showed significant improvement in terms of mobility, pain, and quality of life within six weeks of the treatment.

By Joint Type Analysis

Growing Prevalence of Knee Osteoarthritis Among the Population to Impel Segment Growth

Based on joint type, the market is segmented into knee, hip, hand & wrist, and others.

The knee segment dominated the market in 2023 with the largest share. The dominance is attributed to several factors, such as the rising prevalence of knee OA, the increasing diagnosis rate of the condition among the patient pool, and others.

• According to the 2023 study published in the Lancet, osteoarthritis is the most common form of arthritis, and around 15.0% of the population worldwide is affected by the condition.

The hand & wrist segment is expected to expand at a considerable growth rate during the forecast period. The growing awareness regarding the condition of patients suffering from osteoarthritis, along with increasing diagnoses among the patients, are some of the major factors expected to fuel the growth of the segment.

The hip segment is projected to grow at a nominal CAGR during the forecast period. The rising prevalence of the condition among osteoarthritis patients is one of the major factors anticipated to fuel the growth of the segment.

• According to a 2023 article published by the University of Washington, the prevalence of hip osteoarthritis among patients suffering from osteoarthritis is projected to increase by around 78.6% by 2050.

The others segment is expected to grow owing to the rising prevalence of other joint conditions related to the spine, foot, and ankle, among others. The rising adoption of the treatment among the global population is another major factor driving the growth of the segment.

By Distribution Channel Analysis

Increasing Number of Retail Pharmacies with Pain Injections to Support Segment Growth

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on distribution channel.

The retail pharmacies segment held the largest share of the global market in 2023. The dominance is owed to the increasing number of retail pharmacies supplying joint pain injections globally. The easy accessibility and procurement of injections from retail pharmacies and the availability of these drugs at a discounted rate are some of the major factors contributing to the growth of the segment.

On the other hand, the online pharmacies segment is anticipated to record a significant CAGR during the forecast period. The rising regulatory policies for online sales of prescription drugs in developed countries and the entry of leading e-pharmacy players in Germany, the U.K., and other countries are leading to a shift in patient preference toward online pharmacies.

Along with this, the lower selling prices of the injections by the online pharmacies is another major factor responsible for the growth of the segment.

• For instance, Synvisc injection, used to treat joint pain in osteoarthritis patients, is sold on the Canada Pharmacy website for USD 100-150 per 2ml syringe, whereas the same product costs around USD 300-350 per 2ml syringe in offline stores.

The hospital pharmacies segment is anticipated to grow owing to factors such as the growing hospitalization rate of patients suffering from orthopedic conditions, rising patient visits to hospitals for the diagnosis of the condition, and others.

REGIONAL INSIGHTS

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

In 2023, North America dominated the global joint pain injections market with a share of 45.14% and market size of USD 2.37 billion.

The growing prevalence of osteoarthritis in the U.S. and Canada is one of the prominent factors leading to the increasing adoption of treatment options, including intra-articular injections among this patient population.

• For instance, according to a 2022 article published by the Radiological Society of North America (RSNA), there are around 32.5 million U.S. adults affected by osteoarthritis.

The rising focus of the government bodies in the region on the promotion of the adoption of joint pain injections among the patients by creating awareness and increasing the coverage policies of the products, among others, are some of the factors that are expected to augment the growth of the market in the region.

Asia Pacific market for joint pain injections is expected to grow at the highest CAGR during the forecast period owing to the increasing geriatric population in China, Japan, India, and others, leading to a higher risk of development of various musculoskeletal conditions.

• According to 2022 data published by Population Pyramid, the population aged 60 years and above in Japan was nearly 44.5 million and constituted around 35.8% of the total population.

Europe is projected to expand at a considerable growth rate during the forecast period. The increasing support of government bodies and other healthcare organizations to create awareness about musculoskeletal conditions, available treatment options, and others is expected to spur regional growth during the forecast period.

• For instance, the 2020 European Alliance of Associations for Rheumatology updated the recommendations for the management of knee osteoarthritis and supported the use of hyaluronic acid injections among patients.

Latin America and the Middle East & Africa are expected to expand at a nominal growth rate during the forecast period. The improving healthcare infrastructure, growing healthcare expenditure, and rising prevalence of musculoskeletal conditions in the countries are some of the major factors anticipated to augment the growth of the regions.

• According to a 2020 study published by the World Health Organization (WHO)/International League Associations for Rheumatology Community Oriented Program for the Control of Rheumatic Diseases (COPCORD), the prevalence of osteoarthritis is increasing in Latin American countries, with prevalence rates of 10.5% in Mexico, 4.1% in Brazil, 14.4% in Peru, and 20.4% in Cuba. In addition, knee osteoarthritis accounted for around 45.0% of the total osteoarthritis cases in Latin American countries.


• Similarly, according to a 2020 article published by the National Library of Medicine, the prevalence of knee osteoarthritis in Africa is 21.0% among the population.

The increasing focus of the key players on fueling the adoption of the products in Brazil, Mexico, and others are a few other factors contributing to the growth of the regions.

List of Key Companies in Joint Pain Injections Market

Key Players Focus on R&D Activities to Enhance the Efficiency of Pain Management Products

The global market is fragmented and operated by several players with a broad product portfolio. Some of the prominent players operating in the market include Bioventus, SEIKAGAKU CORPORATION, and Zimmer Biomet, among others. These players increasingly focus on R&D activities to improve the efficiency of pain management products and create awareness regarding the products to cater to the rising demand among the patient population.

• For instance, in September 2021, Bioventus announced that the American Academy of Orthopaedic Surgeons (AAOS) updated the clinical practice guidelines (CPG) and indicated that DUROLANE showed statistically significant results in the management of knee osteoarthritis patients.

Few players, such as Ferring B.V., Dr. Reddy’s, Anika Therapeutics Inc., and Sanofi, among others, have a robust focus on developing and introducing novel products in global markets, which is expected to support their growing joint pain injections market shares.

• For instance, in April 2022, Dr. Reddy’s Laboratories Ltd. launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL in the U.S. for the treatment of arthritis, blood disorders, and several allergic conditions.

Thus, the rising prevalence of various musculoskeletal conditions, including osteoarthritis, among the population, along with the growing treatment rate among patients, is expected to support the market players in developing and introducing novel therapies for the treatment and management of the conditions.

LIST OF KEY COMPANIES PROFILED:

• SEIKAGAKU CORPORATION (Japan)


• Bioventus (U.S.)


• Anika Therapeutics, Inc. (U.S.)


• Zimmer Biomet (U.S.)


• Sanofi (France)


• Pacira BioSciences, Inc. (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Ferring B.V. (Switzerland)


• Dr. Reddy’s Laboratories Ltd. (India)

KEY INDUSTRY DEVELOPMENTS:

• December 2023 – Bioventus agreed to a nationwide contract with Aetna Medicare Advantage plans, wherein over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE, single-injection hyaluronic acid (HA)-based joint-fluid treatment, to treat knee osteoarthritis (OA).


• November 2022 – Anika Therapeutics, Inc. announced that its product Cingal demonstrated positive results in phase III clinical trials and is planning to proceed further for the U.S. FDA approval.


• March 2022 – Sanofi collaborated with IGM Biosciences Inc. to develop, manufacture, and introduce potential therapeutics in the fields of immunology and inflammation.


• January 2022 – SEIKAGAKU CORPORATION announced the establishment of a new company in Canada, SEIKAGAKU NORTH AMERICA CORPORATION, with an aim to expand its geographical presence.


• August 2021 – SEIKAGAKU CORPORATION launched Hylink, a viscosupplementation injection, in Taiwan for the treatment of knee osteoarthritis through TCM Biotech International Corp.

REPORT COVERAGE

The research report provides an overall joint pain injections market scenario. It focuses on key aspects such as leading companies, product, joint type, and distribution channels. Besides this, it offers insights into the trends in the global market, highlights key industry developments, and COVID-19's impact on the market. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market growth in recent years.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 10.4% from 2024-2032
Unit	Value (USD Billion)
Segmentation	By Product Corticosteroid Injections Hyaluronic Acid Injections Platelet Rich Plasma Injections Others
By Joint Type Knee Hip Hand & Wrist Others
By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Geography North America (By Product, Joint Type, Distribution Channel, and Country) U.S. Canada Europe (By Product, Joint Type, Distribution Channel, and Country/Sub-Region) Germany U.K. France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Product, Joint Type, Distribution Channel, and Country/Sub-Region) China Japan India Australia Southeast Asia Rest of the Asia Pacific Latin America (By Product, Joint Type, Distribution Channel, and Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product, Joint Type, Distribution Channel, and Country/Sub-Region) GCC South Africa Rest of the Middle East & Africa